We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Phreesia (PHR) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Read MoreHide Full Article
Wall Street analysts expect Phreesia (PHR - Free Report) to post quarterly loss of $0.37 per share in its upcoming report, which indicates a year-over-year increase of 45.6%. Revenues are expected to be $102.05 million, up 18.9% from the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Phreesia metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts forecast 'Revenus- Subscription and related services' to reach $47.93 million. The estimate points to a change of +21.9% from the year-ago quarter.
Analysts predict that the 'Revenus- Network solutions' will reach $28.06 million. The estimate points to a change of +22.5% from the year-ago quarter.
The consensus estimate for 'Revenus- Payment processing fees' stands at $25.76 million. The estimate indicates a year-over-year change of +9%.
According to the collective judgment of analysts, 'Average healthcare services Clients' should come in at 4,159. Compared to the current estimate, the company reported 3,445 in the same quarter of the previous year.
Based on the collective assessment of analysts, 'Patient payment volume' should arrive at $1.13 billion. Compared to the current estimate, the company reported $989 million in the same quarter of the previous year.
The average prediction of analysts places 'Average revenue per healthcare services client' at $18.20 million. The estimate compares to the year-ago value of $18.27 million.
Shares of Phreesia have experienced a change of -0.5% in the past month compared to the +2.6% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), PHR is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Phreesia (PHR) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Wall Street analysts expect Phreesia (PHR - Free Report) to post quarterly loss of $0.37 per share in its upcoming report, which indicates a year-over-year increase of 45.6%. Revenues are expected to be $102.05 million, up 18.9% from the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Phreesia metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts forecast 'Revenus- Subscription and related services' to reach $47.93 million. The estimate points to a change of +21.9% from the year-ago quarter.
Analysts predict that the 'Revenus- Network solutions' will reach $28.06 million. The estimate points to a change of +22.5% from the year-ago quarter.
The consensus estimate for 'Revenus- Payment processing fees' stands at $25.76 million. The estimate indicates a year-over-year change of +9%.
According to the collective judgment of analysts, 'Average healthcare services Clients' should come in at 4,159. Compared to the current estimate, the company reported 3,445 in the same quarter of the previous year.
Based on the collective assessment of analysts, 'Patient payment volume' should arrive at $1.13 billion. Compared to the current estimate, the company reported $989 million in the same quarter of the previous year.
The average prediction of analysts places 'Average revenue per healthcare services client' at $18.20 million. The estimate compares to the year-ago value of $18.27 million.
View all Key Company Metrics for Phreesia here>>>
Shares of Phreesia have experienced a change of -0.5% in the past month compared to the +2.6% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), PHR is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>